Cyto-Pathology Classification
Cytology AML following essential thrombocythemia Immunophenotype of the blast cells performed by flowcytometry was positive for CD7 (46%), CD13 (80%), CD15 (58%), CD33 (49%), CD34 (50%), CD45 (68%), and HLDR (76%).
Rearranged Ig Tcr
Not done. 
Pathology

Comments
A 52-years old female patient, with a history of thrombocythemia of 2 years duration was presented with symptomatic anemia and hepatosplenomegaly on March, 2012. Blood film showed evidence of leukoerythroblastic picture with 8% blast cells and bone marrow biopsy confirmed myelofibrosis with megakaryocytic hyperplasia demonstrated the presence of 20% myeloblast cells. Conventional cytogenetic analysis of blood and bone marrow samples revealed a rare chromosome abnormality: der(18)t(1;18)(q10;q10) associated with a deletion of the long arm of chromosome 20 in all metaphases.
Unbalanced translocations involving the long arm of chromosome 1 are recurrent chromosome aberrations in patients with various myeloid neoplasms, including myeloproliferative disorders. The centromeric fusion between chromosomes 1 and 18, leading to a normal chromosome 18 substituted with a der(1;18) chromosome observed in our patient has been described in only 5 patients. 4 patients were diagnosed with chronic myeloproliferative disorders (MPD) and 1 patient with complex karyotype with multiple myeloma. Among the 4 patients with MPD, additional chromosome anomaly was detected only in 1 patient (+22), indicating that the der(1;18)(q10;q10) is a primary chromosome anomaly in myeloproliferative disorders. However; as deletion of the long arm of chromosome 20 is a known primary anomaly in myeloid disorders, we cannot exclude the possibility that the der(1;18)(q10;q10) is a secondary anomaly in our case; possibly involved in disease transformation. The unbalanced nature of the rearrangement indicates that gain of 1q and/or loss of 18p might be pathogenetically relevant for neoplastic transformation in this group of patients.
